Cancer and the FRA3B/FHIT fragile locus: It's a HIT

British Journal of Cancer

Volumn 88, Issue 10, 2003, Pages 1501-1506

  Huebner, K ^a   Croce, C M ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Carcinogenesis; Epithelial cancers; FHIT; Fragile sites; Histidine triad; HIT; Tumour suppressor

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN;

APOPTOSIS; BREAST CANCER; CANCER; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CHROMOSOME FRAGILE SITE; CHROMOSOME MAP; COLON CANCER; CORRELATION ANALYSIS; ESOPHAGUS CANCER; FHIT GENE; GENE FUNCTION; GENE LOCUS; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HUMAN; LUNG CANCER; LYMPH NODE METASTASIS; MISMATCH REPAIR; MOUTH CANCER; PRIORITY JOURNAL; SHORT SURVEY; STOMACH CANCER; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER;

ACID ANHYDRIDE HYDROLASES; APOPTOSIS; BASE PAIR MISMATCH; CELL DIVISION; DISEASE PROGRESSION; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; SURVIVAL;

EID: 0038793721     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600937     Document Type: Short Survey

References (41)

1. Andachi H, Yashima, K, Koda M, Kawaguchi K, Kitamura A, Hosoda A, Kishimoto Y, Shiota G, Ito H, Makino M, Kaibara N, Kawasaki H, Murawaki Y (2002) Reduced Fhit expressions associated with mismatch repair deficiency in human advanced colorectal carcinoma. Br J Cancer 87: 441-445
2. Butler D, Collins C, Mabruk M, Leader MB, Kay EW (2002) Loss of Fhit expression as a potential marker of malignant progression in preinvasive squamous cervical cancer. Gynecologic Oncol 86: 144-149
3. Caselli M, Marchisio M, Gaudio M, Saragoni L, Lanza G, Alvisi V, Bertagnolo V, Concu M, Capitani S, Caramelli E (2001) Fhit protein expression in human gastric cancer and related precancerous lesions. Oncol Rep 8: 1233-1237
4. Chang KW, Kao SY, Tzeng RJ, Liu CJ, Cheng AJ, Yang SC, Wong YK, Lin SC (2002) Multiple molecular alterations of FHIT in betel-associated oral carcinoma. J Pathol 196: 300-306
5. Connolly DC, Greenspan DL, Wu R, Ren X, Dunn RL, Shah KV, Jones RW, Bosch FX, Munoz N, Cho KR (2000) Loss of Fhit expression in invasive cervical carcinomas and intraepithelial lesions associated with invasive disease. Clin Cancer Res 6: 3505-3510
6. Dumon KR, Ishii H, Fong LYY, Zanesi N, Fidanza V, Vecchione, A, Baffa R, Trapasso F, During MJ, Huebner K, Croce CM (2001) FHIT gene therapy prevents tumour development in Fhit-deficient mice. Proc Natl Acad Sci USA 98: 3346-3351
7. Fong LYY, Fidanza V, Zanesi N, Lock L, Siracusa L, Mancini R, Siprashvilli Z, Ottey M, Martin SE, Druck T, McCue PA, Croce CM, Huebner K (2000) Muir-Torre-like syndrome in Fhit deficient mice. Proc Natl Acad Sci USA 97: 4742-4747
8. Garinis GA, Gorgouli VG, Mariatos G, Zacharatos P, Kotsinas A, Liloglou T, Foukas P, Kanavaros P, Kastrinakis NG, Vassilakopoulas T, Vogiatzi T, Field JK, Kittas C (2001) Association of allelic loss at the FHIT locus and p53 alterations with tumour kinetics and chromosomal instability in non-small cell lung carcinomas (NSCLCs). J Pathol 193: 55-65
9. Geradts J, Fong KM, Zimmerman PV, Minna JD (2000) Loss of Fhit expression in non-small-cell long cancer: correlation with molecular genetic abnormalities and clinicopathological features. Br J Cancer 82: 1191-1197
10. Guo Z, Wu F, Asplun A, Hu X, Mazurenko N, Kisseljov F, Ponten J, Wilander E (2001) Analysis of intratumorial heterogeneity of chromosome 3p deletions and genetic evidence of polyclonal origin of cervical squamous carcinoma. Mol Pathol 14: 54-61
11. Hao XP, Willis JE, Pretlow TG, Rao JS, MacLennan GT, Talbot IC, Pretlow TP (2000) Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions. Cancer Res 60: 18-21
12. Helland A, Kraggerud SM, Kristensen GB, Holm R, Abeler VM, Huebner K, Borresen-Dale AL, Lothe RA (2000) Primary cervical carcinomas show 2 common regions of deletion at 3p, 1 within the FHIT gene: evaluation of allelic imbalance at FHIT, RB1 and TP53 in relation to survival. Int J Cancer 88: 217-222
13. Herzog CR, Crist KA, Sabourin CL, Kelloff GJ, Boone CW, Stoner GD, You M (2001) Chromosome 3p tumour-suppressor gene alterations in cervical carcinoma. Mol Carcinogen 30: 159-168
14. Holbach LM, von Moller A, Decker C, Junemann AG, Rummelt-Hofmann C, Ballhausen WG (2002) Loss of fragile histidine triad (FHIT) expression and microsatellite instability in periocular sebaceous gland carcinoma in patients with Muir-Torre syndrome. Am J Ophthalmol 134: 147-148
15. Huebner K, Croce CM (2002) FRA3B and other common fragile sites: The weakest Links. Nat Rev Cancer 1: 214-221
16. Huebner K, Garrison PN, Barnes LD, Croce CM (1998) The role of the FRA3B/FHIT locus in cancer. Ann Rev Genet 32: 7-31
17. Huiping C, Kristjansdottir S, Bergthorsson JT, Jonasson JG, Magnusson J, Egilsson V, Ingvarsson S (2002) High frequency of LOH, MSI and abnormal expression of FHIT in gastric cancer. Eur J Cancer 38: 728-735
18. Ingvarsson S, Sigbjornsdottir BI, Huiping C, Jonasson JG, Agnarsson BA (2001) Alterations of the FHIT gene in breast cancer: association with tumour progression and patient survival. Cancer Detect Prev 25: 318-324
19. Kitamura A, Yashima K, Okamoto E, Andachi H, Hosoda A, Kishimoto Y, Shiota G, Ito H, Kaibara N, Kawasaki H (2001) Reduced Fhit expression occurs in the early stage of esophageal tumorigenesis: no correlation with p53 expression and apoptosis. Oncology 61: 205-211
20. Kollias J, Man S, Marafie M, Carpenter K, Pinder S, Ellis IO, Blamey RW, Cross G, Brook JD (2000) Loss of heterozygosity in bilateral breast cancer. Breast Cancer Res Treat 64: 241-251
21. Krivak TC, McBroom JW, Seidman J, Venzon D, Crothers B, MacKoul PJ, Rose GS, Carlson JW, Birrer MJ (2001) Abnormal fragile histidine triad (FHIT) expression in advanced cervical carcinoma: a poor prognostic factor. Cancer Res 61: 438-485
22. Lee JI, Soria JC, Hassan K, Liu D, Tang X, El-Naggar A, Hong WK, Mao L (2001) Loss of Fhit expression is a predictor of poor outcome in tongue cancer. Cancer Res 61: 837-841
23. Lee SH, Kim WH, Kim HK, Woo KM, Nam HS, Kim HS, Kim JG, Cho MH (2001) Altered expression of the fragile histidine triad gene in primary gastric adenocarcinomas. Biochem Biophys Res Commun 284: 850-855
24. Luceri C, Guglielmi F, De Filippo C, Caderni G, Mini E, Biggeri A, Napoli C, Tonelli F, Cianchi F, Dolara P (2000) Clinicopathologic features and FHIT gene expression in sporadic colorectal adenocarcinomas. Scand J Gastroenterol 35: 637-641
25. Mady HH, Melhem MF (2002) FHIT protein expression and its relation to apoptosiS, tumour histologic grade and prognosis in colorectal adenocarcinoma: an immunohistochemical and image analysis study. Clin Exp Metast 19: 351-358
26. Menin C, Santacatterina M, Zambon A, Montagna M, Parenti A, Ruol A, D'Andrea E (2000) Anomalous transcripts and allelic deletions of the FHIT gene in human esophageal cancer. Cancer Genet Cytogenet 119: 56-61
27. Mineta H, Miura K, Takebayashi S, Misawa K, Ueda Y, Suzuki I, Ito M, Wennerberg J (2003) Low expression of fragile histidine triad gene correlates with high proliferation in head and neck squamous cell carcinoma. Oral Oncol 39: 56-63
28. Mori M, Mimori K, Masuda T, Yoshinaga K, Yamashita K, Matsuyama A, Inoue H (2001) Absence of Msh2 protein expression is associated with alteration in the FHIT locus and Fhit protein expression in colorectal carcinoma. Cancer Res 61: 7379-7382
29. Mori M, Mimori K, Shiraishi T, Alder H, Inoue H, Tanaka Y, Sugimachi K, Huebner K, Croce CM (2000) Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus. Cancer Res 60: 1177-1182
30. Morikawa H, Nakagawa Y, Hashimoto K, Niki M, Egashira Y, Hirata I, Katsu K, Akao Y (2000) Frequent altered expression of fragile histidine triad protein in human colorectal adenomas. Biochem Biophys Res Commun 278: 205-210
31. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, Croce CM, Huebner K (1996) The FHIT gene spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint is abnormal in digestive tract cancers. Cell 84: 587-597
32. Pavelic K, Krizanac S, Cacev T, Hadzija MP, Radosevic S, Crnic I, Levanat S, Kapitanovic S (2001) Aberration of FHIT gene is associated with increased tumour proliferation and decreased apoptosis-clinical evidence in lung and head and neck carcinomas. Mol Med 7: 442-453
33. Pylkkanen L, Wolff H, Stjernvall T, Tuominen P, Sioris T, Karjalainen A, Anttila S, Husgafvel-Pursiainen K (2002) Reduced Fhit protein expression and loss of heterozygosity at FHIT gene in tumours from smoking and asbestos-exposed lung cancer patients. Int J Oncology 20: 285-290
34. Rosin MP, Lam WL, Poh C, Le ND, Li RJ, Zeng T, Priddy R, Zhang L (2002) 3p14 and 9p21 loss is a simple tool for predicting second oral malignancy at previously treated oral cancer sires. Cancer Res 62: 6447-6450
35. Shimada Y, Sato F, Watanabe G, Yamasaki S, Kato M, Maeda M, Imamura M. (2000) Loss of fragile histidine triad gene expression is associated with progression of esophageal squamous cell carcinoma, but not with the patient's prognosis and smoking history. Cancer 89: 5-11
36. Tanimoto K, Hayashi S, Tsuchiya E, Tokuchi Y, Kobayashi Y, Yoshiga K, Okui T, Kobayashi M, Ichikawa T (2000) Abnormalities of the FHIT gene in human oral carcinogenesis. Br J Cancer 82: 838-843
37. Teixeira MR, Pandis N, Heim S (2002) Cytogenetic clues to breast carcinogenesis. Genes Chrom Cancer 33: 1-16
38. Terry G, Ho L, Londesborough P, Cuzick J (2002) Abnormal FHIT expression profiles in cervical intraepithelial neoplastic (CIN) lesions. Br J Cancer 86: 376-381
39. Turner B, Ottey M, Potoczek M, Hauck WW, Pequignot E, Keck-Waggoner C, Zimonjic DB, Sevignani C, Aldaz M, McCue P, Palazzo J, Huebner K, Popescu NC (2002) The FHIT/FRA3B locus and repair deficient cancers. Cancer Res 62: 4054-4060
40. van Heerden WFP, Swart TJP, Robson B, Smith T-L, Engelbrecht S, van Heerden MB, van Rensburg EJ, Huebner K (2001) FHIT RNA and protein expression in oral squamous cell carcinomas. Anticancer Res 21: 2425-2428
41. Yang Q, Yoshimura G, Suzuma T, Tamaki T, Umemura T, Nakamura M, Nakamura Y, Wang X, Mori I, Sakurai T, Kakudo K (2001) Clinicopathological significance of fragile histidine triad transcription and protein expression in breast carcinoma. Clin Cancer Res 7: 3869-3873